Industry: Pharmaceuticals
Pharmaceutical startup funding
Drugmakers and pharma service firms raise on approvals, plant capacity and supply contracts, not on one molecule. We help specialty pharma, generics, drug delivery and CDMO teams show what each round pays for.
- Funding routes for specialty pharma, generics, drug delivery and CDMOs
- Models that tie capex, filings and plant use to cash
- Waveup prepares investor materials for pharmaceutical companies: $3B+ raised for 600+ startups since 2014
In short
What is pharmaceutical startup funding?
Pharmaceutical startup funding is the money newer drugmakers and pharma service firms raise to grow. That covers specialty pharma, generics and biosimilars, drug delivery, and CDMOs and CROs. It comes from VCs, private equity, royalty funds, lenders and strategic partners. Bain estimates private equity deals in biopharma reached $80 billion in 2025.
- Who it's for
- Specialty pharma, generics and biosimilars, drug delivery, CDMOs and CROs, pre-seed to Series D+
- What we build
- Investor deck, financial model, valuation, investor list, data room
- Prices
- Deck from $6,000, model from $3,000. Flat fees
- Track record
- $3B+ raised for 600+ startups since 2014
Market data checked on 6 November 2026. Sources are under each section.
Can you still start and fund a pharmaceutical company in 2026?
Yes, if each round pays for a clear step: a filing, a production line or a signed supply deal. Plans that need a factory before they have buyers struggle to raise.
The opportunity
Patent expiries, shortages and new US trade rules are changing who makes medicines, and where.
- US biosimilar approvals reached new highs in 2024 and 2025
- Patented drug imports now face US tariffs; generics are left out for now
- Shortages persist, from cancer drugs to imaging contrast agents
The problem
Generics fill most US prescriptions, yet take just 11.6% of prescription drug spending. With margins that thin, investors test cost per unit before growth plans.
Market size
How much does the US spend on prescription drugs, and what is changing?
US retail spending on prescription drugs reached $467.0 billion in 2024, CMS reports. Four trends shape where newer drugmakers and service firms can grow:
- Fastest growth: CMS expects retail drugs to outpace its other major spending categories, at 5.7% a year to 2034
- More volume: medicine use worldwide will near 4 trillion daily doses by 2030, IQVIA forecasts
- Onshoring: makers with an approved US production plan pay a 20% tariff on patented imports
- Shortages: 87 new US drug shortages were reported in the first nine months of 2026
Private capital
Where does private money for pharma companies come from now?
Pharma services buyouts reached a record value in 2025. Bain estimates private equity deals across biopharma came to $80 billion that year.
biopharma deals by private equity firms in 2025, by Bain's estimate
of 2025's pharma services deal value came from a single CDMO buyout
average yearly fall in pharma services deal count since the 2023 peak
Who funds pharmaceutical companies, from startup to buyout?
Healthcare private equity, product-finance and royalty funds, and investors that focus on generics and biosimilars. A few names by type. For venture firms that back drug development, see our guide to venture capital in life sciences.
Investor database
Pharma investors in our database
The funds with the most pharma investments. Pick a stage, or open a fund for its cheque sizes.
Top 5 by pharma investments
Investments by industry
- Healthtech & Wellness47%
- Biotech26%
- Pharma20%
- Rounds
- SeedSeries ASeries BSeries C+
- Average cheque
- $100K–$500K$500K–$1M$1M–$3M$3M–$10M
- Based in
- Chicago, United States
- Invests in
- USA
502 investments in total, 18 tagged Pharma.Open the full fund profile
Investments by industry
- Healthtech & Wellness60%
- Pharma18%
- Biotech15%
- Rounds
- Series ASeries BSeries C+
- Average cheque
- Not listed
- Based in
- Menlo Park, California, United States
128 investments in total, 13 tagged Pharma.Open the full fund profile
Investments by industry
- Healthtech & Wellness41%
- Biotech36%
- Pharma18%
- Rounds
- SeedSeries ASeries BSeries C+
- Average cheque
- $0–$100K$100K–$500K$500K–$1M$1M–$3M$3M–$10M
- Based in
- Boston, United States
- Invests in
- USA
141 investments in total, 11 tagged Pharma.Open the full fund profile
Investments by industry
- Healthtech & Wellness46%
- Biotech25%
- Pharma16%
- Rounds
- SeedSeries ASeries BSeries C+
- Average cheque
- Not listed
- Based in
- United States
- Invests in
- Israel, Europe, USA +1
231 investments in total, 11 tagged Pharma.Open the full fund profile
Investments by industry
- Healthtech & Wellness38%
- Biotech33%
- Pharma17%
- Rounds
- SeedSeries ASeries C+
- Average cheque
- $0–$100K$100K–$500K$500K–$1M$1M–$3M$3M–$10M
- Based in
- San Francisco, United States
- Invests in
- USA
196 investments in total, 10 tagged Pharma.Open the full fund profile
From our investor database.
What makes investors cautious about pharma companies?
Our Fundraising 2025 study asked 56 VCs why they pass. Revenue growth, unit economics, burn and missed milestones led the list, ahead of defensibility and crowded categories. Pharma adds four tests of its own.
Crowded products
Generic makers compete mostly on price, and new rivals keep filing. The FDA received 600 new generic drug applications in fiscal 2025.
What investors ask
- How will your margin hold when the next three rivals launch?
What your deck shows
- Products with few rivals: complex, injectable or hard to make
- Cost per pack against the cheapest competitor
FDA fees before the first sale
The FDA's fee for one generic drug application is $375,684 in fiscal 2027. Each plant named in an approved application also pays a yearly facility fee.
What investors ask
- How many filings does this round pay for, and when does the first one earn?
What your deck shows
- A filing plan with fees and expected approval dates
- Cash runway to the first launch
Tariffs on patented imports
Since September 2026, many patented medicines imported into the US face tariffs of up to 100%. Generics and biosimilars are left out of these tariffs for now.
What investors ask
- Where is each product made, and what would a tariff do to its margin?
What your deck shows
- Cost per pack, landed, by country of manufacture
- A plan for US supply if a buyer asks for one
New rules on biotech suppliers
A US law of December 2025 limits federal contractors' use of listed biotechnology companies of concern. The first full list is due by 18 December 2026.
What investors ask
- Which of your suppliers, partners or customers could the list touch?
What your deck shows
- Every outsourced step, with a named backup supplier
- Capacity you could offer customers who switch
How we help you raise
Flat fees agreed before we start. No success fee on advisory work.
Products, filings and capacity, told as one story an investor can test.
Batches, yields, prices after rivals launch and cash, month by month.
A range you can defend against buyout and listed-peer multiples.
Healthcare private equity, royalty funds and VCs that fit your stage.
Licences, inspection history and supply contracts, ready for review.
For a sale to a drugmaker, a CDMO group or a buyout fund.
Who we are
Waveup is a London-based fundraising and growth advisory, working in 60+ countries and 90+ industries. Since 2014 we have built the decks, models, CIMs and valuations behind $3B+ raised for 600+ startups. Biotech and pharma are the largest group among our 54+ deep-tech projects.
About usPharmaceutical startup funding FAQ
How do pharmaceutical startups get funding?
How much money does it take to start a pharmaceutical company?
Who invests in generic drug makers and CDMOs?
What do investors look for in a pharmaceutical company?
Do US tariffs apply to generic drugs?
How much does help with a pharmaceutical raise cost?
Industries we work with
Pharmaceuticals
- Pharmaceuticals
- Life Sciences
- PharmaTech
Related industries
Raising for a pharmaceutical company?
Send us your products, your filings and the round you plan. We'll tell you how investors are likely to read them.



